Evidence map›Paper›PMID 37867235›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

A Pro-Metastatic Derivatives Eliminator for In Vivo Dual-Removal of Circulating Tumor Cells and Tumor-Derived Exosomes Impedes their Biodistribution into Distant Organs.

Ying Sun, Lei Xing, Jun Luo, Ming-Tao Yu, Xiao-Jie Wang, Yi Wang, Tian-Jiao Zhou, Hu-Lin Jiang

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ying SunState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Lei XingState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Jun LuoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Ming-Tao YuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Xiao-Jie WangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Yi WangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Tian-Jiao ZhouState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Hu-Lin JiangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.ORCID 0000-0002-1620-1777
China Pharmaceutical University · CN

Funding

China Postdoctoral Science Foundation 2021M703598China Postdoctoral Science Foundation 2022M720173Double First-Rate construction plan of China Pharmaceutical University CPU2018GY06Double First-Rate construction plan of China Pharmaceutical University CPU2022QZ18Jiangsu Funding Program for Excellent Postdoctoral Talent and International Postdoctoral Exchange Fellowship Program 2022Ministry of Education of ChinaNational Natural Science Foundation of China 82020108029National Natural Science Foundation of China 82073398Priority Academic Program Development of Jiangsu Higher Education InstitutionsProject of State Key Laboratory of Natural Medicines, China Pharmaceutical University SKLNMZZ202021State Administration of Foreign Experts Affairs of China B16046
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) and tumor-derived exosomes (TDEs) play an irreplaceable role in the metastatic cascade and preventing them from reaching distant organs via blood circulation helps to reduce the probability of cancer recurrence and metastasis. However, technologies that can simultaneously prevent CTCs and TDEs from reaching distant organs have not been thoroughly developed until now. Here, inspired by hemoperfusion, a pro-metastatic derivative eliminator (PMDE) is developed for the removal of both CTCs and TDEs from the peripheral blood, which also inhibits their biodistribution in distant organs. This device is designed with a dual antibody-modified immunosorbent filled into a capture column that draws peripheral blood out of the body to flow through the column to specifically capture CTCs and TDEs, followed by retransfusing the purified blood into the body. The PMDE can efficiently remove CTCs and TDEs from the peripheral blood and has excellent biocompatibility. Interestingly, the PMDE device can significantly inhibit the biodistribution of CTCs and TDEs in the lung and liver by scavenging them. This work provides a new perspective on anti-metastatic therapy and has broad prospects in clinical applications to prevent metastasis and recurrence.

Indexed as

ExosomesNeoplastic Cells, CirculatingHumansLungNeoplasm Recurrence, LocalTissue Distributionbiodistributioncirculating tumor cellsdual removalhemoperfusionmetastatic cascadetumor-derived exosomes

Identifiers

PMID37867235
PMCPMC10700241
OpenAlexW4387866520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.